Reneuron Regulatory News (RENE)

ReNeuron Group plc

ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce the appointment of Dr Claudia D'Augusta as a Non-executive Director of the Company, effective from the date of the Company's Annual General Meeting on 6 September 2017. She will also chair the Company's Audit Committee.

Dr D'Augusta has over twenty years' experience in corporate finance, capital markets and M&A. She is the Chief Financial Officer of TiGenix NV, a leading international cell therapy company listed on both Euronext Brussels and, more recently, on NASDAQ following a successful US IPO in 2016. TiGenix's lead product has been filed for regulatory approval in Europe for the treatment of a severe complication of Crohn's disease.

Before joining TiGenix in 2004, Dr D'Augusta was finance director of Aquanima (Santander Group). Previous experience includes roles in corporate finance and M&A at Deloitte & Touche in Milan and Apax Partners in Madrid. Dr D'Augusta holds a degree in Economics and a Ph.D. in Business Administration from the University of Bocconi, Italy.

Commenting on Dr D'Augusta's appointment, John Berriman, Chairman of ReNeuron, said:

"I am delighted to welcome Claudia to the Board of the Company, and to its Audit Committee. Her broad and extensive experience in Europe and US corporate finance, in particular in the cell therapy sector, will be invaluable to ReNeuron and its management team."

Commenting on her appointment, Dr D'Augusta said:

"I look forward to joining the Board of ReNeuron and contributing to the Company as it continues to develop and moves closer to realising value from its novel cell-based therapies targeting areas of unmet medical need."

Disclosures in accordance with the AIM Rules

Dr Claudia D'Augusta, aged 48, is, or has been, a director or partner of the following companies or partnerships during the past five years:

Current Directorships and Partnerships Past Directorships and Partnerships in theprevious five years

Tigenix SAU Tigenix Limited

Tigenix US, Inc

There are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

ENDS

ENQUIRIES:

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.